Description

1(6H)-Pyridazineacetic Acid, 4-(2-Cyclohexylphenoxy)-α-(Cyclopentylmethyl)-6-Oxo- is a high-purity, advanced pharmaceutical intermediate designed for the synthesis of complex active pharmaceutical ingredients (APIs). This compound is critical for research and development programs targeting novel therapeutic agents, offering a precise and reliable building block for medicinal chemistry. It is primarily utilized by pharmaceutical R&D laboratories, contract research organizations (CROs), and fine chemical manufacturers engaged in the development of new drug candidates.

Application

• Pharmaceutical Intermediate: Key building block in the synthesis of novel, high-value active pharmaceutical ingredients (APIs).
• Medicinal Chemistry Research: Used in lead optimization and structure-activity relationship (SAR) studies for new drug discovery.
• Contract Manufacturing: Sourced by CDMOs (Contract Development and Manufacturing Organizations) for cGMP production of clinical trial materials.
• Preclinical Development: Essential for producing compounds required for pharmacological and toxicological evaluations.
• Academic Research: Utilized in university and institutional labs for exploratory research in organic and medicinal chemistry.
• Process Chemistry: Serves as a starting material or intermediate in the development and scale-up of efficient synthetic routes.

Basic Information

Product Name	1(6H)-Pyridazineacetic Acid, 4-(2-Cyclohexylphenoxy)-α-(Cyclopentylmethyl)-6-Oxo-
CAS No.	1191454-09-7
Molecular Formula	C25H32N2O4
Molecular Weight	424.54 g/mol
Synonyms	4-(2-Cyclohexylphenoxy)-α-(cyclopentylmethyl)-6-oxo-1,6-dihydropyridazine-1-acetic acid; 4-(2-Cyclohexylphenoxy)-α-(cyclopentylmethyl)-6-oxo-1,6-dihydropyridazineacetic acid; 1(6H)-Pyridazineacetic acid, 4-(2-cyclohexylphenoxy)-α-(cyclopentylmethyl)-6-oxo-; UNII-9I4V8P8W4R; 9I4V8P8W4R; 1191454-09-7; 4-(2-Cyclohexylphenoxy)-α-(cyclopentylmethyl)-6-oxo-1,6-dihydropyridazine-1-acetic Acid
EINECS	Contact for details

Quality Control

Our products undergo rigorous quality testing to ensure compliance with industry standards for pharmaceutical intermediates. We implement strict in-process controls and final release testing, including identity confirmation, purity assays, and impurity profiling. Certificates of Analysis (COA) are available upon request, detailing batch-specific results. Our quality management system supports the production of materials suitable for use in regulated environments, including cGMP for clinical trial applications.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry, well-ventilated area at controlled room temperature (typically 15-25°C). Keep away from incompatible materials. For long-term storage, consider storage under an inert atmosphere to maintain product integrity.

Specification

Item	Specification
Appearance	White to off-white solid
Identification (IR)	Conforms to structure
Identification (HPLC)	Retention time matches reference standard
Assay (HPLC)	≥ 98.0%
Related Substances (HPLC)	Total impurities ≤ 2.0% Any single impurity ≤ 1.0%
Residual Solvents (GC)	Complies with ICH Q3C guidelines
Loss on Drying	≤ 0.5%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.